Literature DB >> 1984377

Epidural morphine with butorphanol for postoperative analgesia after cesarean delivery.

C D Lawhorn1, J D McNitt, E E Fibuch, J T Joyce, R J Leadley.   

Abstract

Epidural morphine has been used more and more to provide long-lasting postoperative analgesia after cesarean delivery. However, the incidence of pruritus (20%-93%) and nausea (17%-60%) detract from the usefulness of epidural morphine. The purpose of this study was to evaluate, in 30 patients having epidural anesthesia for cesarean delivery, the analgesic efficacy and side effects when a combination of epidural morphine, a mu-receptor agonist, and butorphanol, a mu-receptor antagonist and kappa-receptor agonist, was administered. After clamping of the umbilical cord, patients received 4 mg epidural morphine with 3 mL of normal saline (group 1), 4 mg epidural morphine with 1 mg butorphanol and 2 mL of normal saline (group 2), or 4 mg epidural morphine with 3 mg butorphanol (group 3). Patients were monitored for 24 h after administration of the study medications. There were no significant differences between the groups in visual analogue pain scores, time to first analgesic request, respiratory rate, or Trieger dot test performance in the 24 h immediately after these epidural injections. There were three patients in group 1 and one patient in group 2 who experienced oxygen saturations less than 90%. (No patients in group 3 developed an oxygen saturation less than 92%.) The patients in group 3 did not require treatment for pruritus or nausea, a response significantly different (P less than 0.001 and P less than 0.05, respectively) from group 1 or group 2.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984377     DOI: 10.1213/00000539-199101000-00009

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  9 in total

1.  Effects of butorphanol on morphine-induced itch and analgesia in primates.

Authors:  Heeseung Lee; Norah N Naughton; James H Woods; Mei-Chuan Ko
Journal:  Anesthesiology       Date:  2007-09       Impact factor: 7.892

Review 2.  Neuraxial opioid-induced itch and its pharmacological antagonism.

Authors:  Mei-Chuan Ko
Journal:  Handb Exp Pharmacol       Date:  2015

3.  Intravenous butorphanol administration reduces intrathecal morphine-induced pruritus after cesarean delivery: a randomized, double-blind, placebo-controlled study.

Authors:  Zhen Wu; Mingjian Kong; Ning Wang; Roderick J Finlayson; Q H De Tran
Journal:  J Anesth       Date:  2012-06-07       Impact factor: 2.078

Review 4.  Pathophysiology and management of opioid-induced pruritus.

Authors:  Arjunan Ganesh; Lynne G Maxwell
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Continuous epidural morphine/butorphanol infusion following selective dorsal rhizotomy in children.

Authors:  C D Lawhorn; F A Boop; R E Brown; P D Andelman; M L Schmitz; P J Kymer; R Shirey
Journal:  Childs Nerv Syst       Date:  1995-11       Impact factor: 1.475

6.  [The clinical use of spinal opioids, part 2].

Authors:  N Rawal
Journal:  Schmerz       Date:  1996-10-28       Impact factor: 1.107

7.  Comparative analgesic efficacy of buprenorphine or clonidine with bupivacaine in the caesarean section.

Authors:  Kiran Agarwal; Navneet Agarwal; Vijender Agrawal; Ashok Agarwal; Mahender Sharma; Kanupriya Agarwal
Journal:  Indian J Anaesth       Date:  2010-09

8.  Non-canonical Opioid Signaling Inhibits Itch Transmission in the Spinal Cord of Mice.

Authors:  Admire Munanairi; Xian-Yu Liu; Devin M Barry; Qianyi Yang; Jun-Bin Yin; Hua Jin; Hui Li; Qing-Tao Meng; Jia-Hang Peng; Zhen-Yu Wu; Jun Yin; Xuan-Yi Zhou; Li Wan; Ping Mo; Seungil Kim; Fu-Quan Huo; Joseph Jeffry; Yun-Qing Li; Rita Bardoni; Michael R Bruchas; Zhou-Feng Chen
Journal:  Cell Rep       Date:  2018-04-17       Impact factor: 9.423

Review 9.  Neuraxial opioid-induced pruritus: An update.

Authors:  Kamal Kumar; Sudha Indu Singh
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2013-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.